Markets
Stocks
Funds
Sectors
Tools
Treasury & Bonds
Overview
Market News
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
My Portfolio
Pieris Pharma (NQ: PIRS)
3.260 USD  -0.010 (-0.31%)
Official Closing Price  /  Updated: 4:40 PM EST, Nov 20, 2018  /  Add to My Watchlist      
View: Quote News
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 796,200
Open 3.200
Bid (Size) 2.180 (1)
Ask (Size) 4.190 (10)
Prev. Close 3.270
Today's Range 3.070 - 3.260
52wk Range 3.040 - 9.750
Shares Outstanding 53,980,359
Dividend Yield N/A
Performance
YTD
-57.94%
-57.94%
1 Month
-32.51%
-32.51%
3 Month
-37.79%
-37.79%
6 Month
-45.30%
-45.30%
1 Year
-47.50%
-47.50%
Top News
More News
Pieris Pharmaceuticals to Present at Investor Conferences in November
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and... Read More
from GlobeNewswire News Releases
Pieris Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and... Read More
from GlobeNewswire News Releases
More News
Read More
Pieris Pharmaceuticals to Host Third Quarter 2018 Investor Call and Corporate Update on November 7, 2018
from GlobeNewswire News Releases
Pieris Pharmaceuticals Appoints Matthew L. Sherman, M.D., to its Board of Directors
from GlobeNewswire News Releases
New Research Coverage Highlights Dorian LPG, Avadel Pharmaceuticals, Pieris Pharmaceuticals, Resolute Energy, American Public Education, and THL Credit — Consolidated Revenues, Company Growth, and Exp
from GlobeNewswire News Releases
Pieris Pharmaceuticals to Present Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/ONC0055 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
from GlobeNewswire News Releases
Pieris Pharmaceuticals to Present at Investor Conferences in October
from GlobeNewswire News Releases
Pieris Pharmaceuticals to Present Preclinical Data for Inhaled IL-4R? Antagonist AZD1402/PRS-060 at the ERS International Congress 2018
from GlobeNewswire News Releases
Analysts Anticipate 25% Gains Ahead For IEIH
category ETFs
from ETF Channel
Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil. to its Board of Directors
from GlobeNewswire News Releases
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.